轻度认知障碍和轻度Alzeimer病的磁共振波谱分析  

A study on mild cognitive impairment and mild Alzeimer＇s disease using MRS

作　　者：许志祥[1] 郭春妮[1] 赵圣杰[1] 王铭琴[1] 胡运胜[2] 陈维杰[3] 赵永波[1] 

机构地区：[1]上海交通大学附属第一人民医院神经科,200080 [2]上海交通大学附属第一人民医院放射科,200080 [3]同济大学附属第十人民医院老年科

出　　处：《神经疾病与精神卫生》2009年第4期285-287,共3页Journal of Neuroscience and Mental Health

基　　金：上海市科委基础研究重大项目（07DJ14005）;上海市市级医院新兴前沿技术联合攻关项目（SHDC12006108）;中国博士后科学基金资助项目（20060390635）

摘　　要：目的探讨氢质子磁共振波谱（1H—MRs）在轻度认知障碍（MCI）、轻度Alzheimer病（AD）诊断与鉴别诊断中的作用。方法对20例MCI患者、20例AD患者、20例正常对照者行。H—MRS检查，采用点分辨自旋回波波谱序列（PRESS），测定双侧内侧颞叶的N-乙酰天门冬氨酸（NAA）、胆碱（Cho）和肌醇（mI）与肌酸（Cr）的比值，并比较各组闻NAA／Cr、mI／Cr、Cho／Cr比值的差别。结果轻度AD组及MCI组与正常对照组间双侧NAA／Cr有显著性差异（P〈0．05），MCI组、轻度AD组、正常对照组三组间双侧mI／Cr有显著性差异（P〈0．05），三组间Cho／Cr比值差异无统计学意义。结论1H—MRs能无创性提供MCI、AD患者脑部的代谢情况，NAA／Cr降低和mI／Cr升高有助于MCI、轻度AD的早期诊断。Objective To evaluate the roles of proton magnetic resonance spectroscopy （1H- MRS） in the diagnosis and differential diagnosis of mild cognitive impairment （MCI） and mild Alzheimer＇s diseases （AD）. Methods 1 H--MRS was performed in the bilateral medial temporal lobes of 20 MCI patients, 20 mild AD patients and 20 normal controls with use of point resolved spectroscopy （PRESS）. The ratios of NAA/Cr, Cho/Cr, MI/Cr were determined and compared. Results Patients with mild AD showed a significant reduction in NAA/Cr ratio, and a significant increase in MI/Cr ratio in the bilateral medial temporal lobes compared to control subjects. Patients with MCI showed a significant increase in MI/Cr in the bilateral medial temporal lobes compared to control subjects. There was a statistical difference in MI/Cr between patients with AD and patients with MCI. No significant difference was shown in Cho/Cr ratio among three groups. Conclusions 1 H--MRS can non--invasively provide the metabolism status of the brains of patients suffering from MCI or mild AD, The reduction in NAA/Cr and increase in MI/Cr in the bilateral medial temporal lobes would be useful for the early diagnosis of patients with mild AD and MCI.

关 键 词：轻度认知障碍 Alzeimer病 氢质子磁共振波谱分析 

分 类 号：R739.41[医药卫生—肿瘤] R749.16[医药卫生—临床医学]